Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Prudhon

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Current Gene Therapy|August 13, 2015
Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfallsDelphine Trochet, Bernard Prudhon, Stéphane Vassilopoulos, et al.
Journal of Molecular Medicine (Berlin, Germany)|February 4, 2010
Dynamin 2 and human diseasesAnne-Cécile Durieux, Bernard Prudhon, Pascale Guicheney, et al.
Molecular Therapy. Nucleic Acids|September 14, 2016
Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicingDelphine Trochet, Bernard Prudhon, Arnaud Jollet, et al.
Scientific Reports|February 9, 2019
Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse modelAnaïs Fongy, Sestina Falcone, Jeanne Lainé, et al.
Basic Research in Cardiology|December 22, 2004
Administration of insulin-like growth factor-1 (IGF-1) improves both structure and function of delta-sarcoglycan deficient cardiac muscle in the hamsterArmelle Serose, Bernard Prudhon, André Salmon, et al.
Neuromuscular Disorders : NMD|April 9, 2008
A novel mutation in the dynamin 2 gene in a Charcot-Marie-Tooth type 2 patient: clinical and pathological findingsMarc Bitoun, Tanya Stojkovic, Bernard Prudhon, et al.
Molecular Therapy. Nucleic Acids|September 12, 2022
Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutationsSwati Dudhal, Lylia Mekzine, Bernard Prudhon, et al.
Molecular Therapy. Nucleic Acids|March 14, 2022
Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathyDelphine Trochet, Bernard Prudhon, Lylia Mekzine, et al.
Traffic (Copenhagen, Denmark)|February 29, 2012
A centronuclear myopathy--dynamin 2 mutation impairs autophagy in miceAnne-Cécile Durieux, Stéphane Vassilopoulos, Jeanne Lainé, et al.
Human Mutation|July 23, 2009
Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosisMarc Bitoun, Anne-Cécile Durieux, Bernard Prudhon, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Gene Therapy|August 13, 2015
Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfallsDelphine Trochet, Bernard Prudhon, Stéphane Vassilopoulos, et al.
Journal of Molecular Medicine (Berlin, Germany)|February 4, 2010
Dynamin 2 and human diseasesAnne-Cécile Durieux, Bernard Prudhon, Pascale Guicheney, et al.
Molecular Therapy. Nucleic Acids|September 14, 2016
Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicingDelphine Trochet, Bernard Prudhon, Arnaud Jollet, et al.
Scientific Reports|February 9, 2019
Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse modelAnaïs Fongy, Sestina Falcone, Jeanne Lainé, et al.
Basic Research in Cardiology|December 22, 2004
Administration of insulin-like growth factor-1 (IGF-1) improves both structure and function of delta-sarcoglycan deficient cardiac muscle in the hamsterArmelle Serose, Bernard Prudhon, André Salmon, et al.
Neuromuscular Disorders : NMD|April 9, 2008
A novel mutation in the dynamin 2 gene in a Charcot-Marie-Tooth type 2 patient: clinical and pathological findingsMarc Bitoun, Tanya Stojkovic, Bernard Prudhon, et al.
Molecular Therapy. Nucleic Acids|September 12, 2022
Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutationsSwati Dudhal, Lylia Mekzine, Bernard Prudhon, et al.
Molecular Therapy. Nucleic Acids|March 14, 2022
Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathyDelphine Trochet, Bernard Prudhon, Lylia Mekzine, et al.
Traffic (Copenhagen, Denmark)|February 29, 2012
A centronuclear myopathy--dynamin 2 mutation impairs autophagy in miceAnne-Cécile Durieux, Stéphane Vassilopoulos, Jeanne Lainé, et al.
Human Mutation|July 23, 2009
Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosisMarc Bitoun, Anne-Cécile Durieux, Bernard Prudhon, et al.
Pageof 2